Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mojun Zhu (NPI 1376923581)

Field	Value
Entity Type	Individual
Organization	Mojun Zhu
Address	13400 E Shea Blvd
City	Scottsdale
State	AZ
ZIP	85259
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 2, 2015

Payer Source	Total Paid
Medicare	$947.4K
Medicaid	$0

Key Findings

This provider is effectively single-payer by volume: total Medicare revenue is $947.4K and there is no Medicaid billing on file, so Medicare drives this practice's public-payer activity and Medicaid-focused contract discussions would have little direct claim history to evaluate. The absence of Medicaid claims suggests the provider's revenue exposure and payer negotiation leverage are concentrated in the Medicare market.

Revenue is highly concentrated in three biologic/immunotherapy agents: J9271 accounts for 40.9% of Medicare revenue, J9144 accounts for 25.3%, and J9299 accounts for 15.3%, and the precomputed top-3 share is 81.4% of total Medicare revenue. This concentration indicates the bulk of billed dollars come from a small set of high-cost injectable cancer therapies rather than a broad mix of low-revenue visit codes.

The code mix and descriptions indicate a clinic-based oncology infusion practice focused on immune checkpoint inhibitors and monoclonal antibodies: the top codes are J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab), and the billing set also includes chemotherapy administration and add-on infusion codes such as 96413, 96417, 96375 and G0498. Presence of supportive agents like J2506 (pegfilgrastim) and biosimilar rituximab Q5119 further supports a combined oncology/hematology infusion and supportive-care service line.

Competitive standing on the headline biologics is modest nationally: J9271 ranks #1157 of 1841 providers nationally (36th percentile) and is labeled in the data as "typical, unremarkable volume," J9144 ranks #407 of 615 (34th percentile, "typical, unremarkable volume"), and J9299 ranks #457 of 505 (9th percentile, also labeled "typical, unremarkable volume"). These rank/percentile positions imply the provider is not a dominant national center for these agents but operates at a typical volume level for oncology providers billing the drugs.

The practice records nontrivial evaluation-and-management activity alongside infusion revenue: 99215 generated $14.6K (103 claims) and ranks #28744 of 145531 providers nationally (80th percentile), a position described in the dataset as "typical, unremarkable volume." This suggests the provider combines higher-complexity office visits with infusion services, consistent with ongoing management of complex oncology patients rather than only episodic drug administration.

Several secondary chemotherapy and supportive-care codes contribute only small shares of revenue and are reported at lower national standing; for example, J2506 (pegfilgrastim) generated $14.6K but ranks #556 of 586 providers nationally (3th percentile) and J9264 (nab‑paclitaxel) generated $27.9K and ranks #106 of 118 providers nationally (9th percentile), both labeled "typical, unremarkable volume" in the dataset. These patterns indicate limited use of some supportive therapies and certain cytotoxic agents relative to national peers, reinforcing the emphasis on a few high-revenue biologics.

The provider has an established NPI tenure that supports a stable local presence: NPI enumerated (registered) 2015-06-02 (~11 years ago). This multi-year enumeration aligns with the sustained Medicare billing profile dominated by infusible oncology agents.

For network and contracting implications, the combination of concentrated Medicare revenue ($947.4K) with no Medicaid billing suggests strategic alignment should prioritize Medicare-managed care and oncology drug reimbursement models; Medicaid-network value is limited by absence of claims history. Any payer or partner evaluating this provider should weight oncology drug reimbursement and buy-and-bill arrangements more heavily than Medicaid access or broad ambulatory primary-care throughput.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

43 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,200	$40	$387.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,300	$40	$239.5K
J9299	Injection, nivolumab, 1 mg	6,040	$20	$145K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,450	$20	$33.4K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	2,790	$10	$27.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	260	$110	$27.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	100	$140	$14.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	170	$90	$14.6K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	70	$140	$9.2K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	30	$210	$6.4K

Showing 1–10 of 43

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 43 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Mojun Zhu — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

43 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	80	10,000	$40	$487.4K
J9144	7	40	8,370	$40	$349.9K
J9299	8	30	7,480	$20	$290K
Q5119	12	40	1,480	$20	$42.6K
J9264	3	10	4,000	$10	$38K
J2506	13	20	220	$80	$29.3K
96413	27	230	190	$100	$24.8K
99214	6,584	10,410	120	$80	$20.6K
J9217	54	140	120	$130	$19.7K
J3490	23	100	40	$90	$17.1K

Showing 1–10 of 43

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mojun Zhu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic Health System-southeast Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$13.7M
Mayo Clinic Arizona	AZ	General Acute Care Hospital	$0	$12.5M
Mayo Clinic Hospital-rochester	MN	General Acute Care Hospital	$0	$11.5M
Sachin Mehta	AZ	Retina Specialist (Ophthalmology) Physician	$4.4M	$11.8K
Mayo Clinic Arizona	AZ	Clinical Medical Laboratory	$3.1M	$76.8K
Ryan Robetorye	AZ	Clinical Pathology/Laboratory Medicine Physician	$2.3M	$0
Allison Rosenthal	AZ	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Mojun Zhu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dsf Of The Valley, Inc	AZ	Durable Medical Equipment & Medical Supplies	$0	$27.4M
Lisa Sproat	AZ	Hematology & Oncology Physician	$1.9M	$0
Cecilia Arana Yi	AZ	Hematology & Oncology Physician	$1.8M	$0
Januario Castro	AZ	Hematology & Oncology Physician	$1.6M	$0
Nathan Punwani	AZ	Hematology & Oncology Physician	$1.6M	$0
Cassandra Moore	AZ	Hematology & Oncology Physician	$1.5M	$0
Mohamad Sonbol	AZ	Hematology & Oncology Physician	$1.5M	$0
Ba Nguyen	AZ	Diagnostic Radiology Physician	$1.4M	$0
Felipe Martinez	AZ	Nuclear Medicine Physician	$1.3M	$0
Karen Anderson	AZ	Hematology & Oncology Physician	$1.2M	$0

Mojun Zhu — Billing Profile & Reimbursement Data

Sign up for Mojun Zhu — Billing Profile & Reimbursement Data policy alerts

Mojun Zhu — Billing Profile & Reimbursement Data

Sign up for Mojun Zhu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References